News | Mammography | June 30, 2017

Nation’s largest independent provider of breast screening services recognized for improving technology, leading to fewer recalls and higher retention rates

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the Dallas Business Journal. Rankings of the publication’s third annual research project were based on both private and public companies with revenue between $25 million and $750 million. Fifty-three companies that met the annual revenue requirements in the 2017 Middle Market 50 were awarded at the 2017 Middle Market 50 Awards Dinner at the Ritz Carlton in Dallas.

Headquartered in Addison, Texas, Solis currently operates 37 centers across six major markets – North Texas; Houston, Texas; Phoenix, Ariz.; Columbus, Ohio; Greensboro, N.C.; and, through its acquisition of Washington Radiology, the D.C. metropolitan area. The company operates both wholly-owned centers and multiple joint ventures with hospital partners. Solis Mammography (including Washington Radiology) serves more than 600,000 patients each year with highly-specialized breast imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy.

Over the past three years, the company has committed $16 million to upgrade all of its centers with 3-D mammography (also known as digital breast tomosynthesis), lowering unnecessary recalls by 37 percent and increasing cancer detection by 54 percent. Taken together, these changes have earned the company a 76 percent annual retention rate with returning patients, far higher than the national average of 53 percent.

Under the leadership of James Polfreman, the company has more than doubled its footprint since he joined the company in 2011, increasing revenue by more than 250 percent and creating a fivefold increase in bottom line, earnings before interest, tax, depreciation and amortization (EBITDA).

For more information: www.solismammo.com


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
Subscribe Now